A few of the ASX 200 stocks have shown resilience during the recent market turbulence. No doubt, these find mention among the growing companies to invest in
CSL Ltd (ASX: CSL)
CSL Ltd (ASX: CSL) achieved a strong result in first half of FY25. Revenue rising 5% to US$8.48B at constant currency and NPATA also up 5% reaching US$2.11B. Net profit after tax raised 7% to US$2.04 billion at constant currency. Earnings per share based on NPATA rose 4% to US$4.36. The company, among the best growth stocks to buy now, declared an interim dividend of US$1.30 per share, equivalent to A$2.08 a 16% increase. CSL reaffirmed its full year FY25 guidance, projecting NPATA between US$3.2 billion and US$3.3 billion representing 10–13% growth over FY24. Revenue for the full year is expected to increase by 5–7% at constant currency.
Strong demand in core immunoglobulin (Ig) therapies continues to drive CSL Behring’s performance supported by growing plasma donations and efficiency gains in plasma collection. Also, the RIKA system rollout is set to complete by year end, contributing to margin improvements. New therapies such as ANDEMBRY® received approval in Australia and the UK with positive regulatory movement in the EU and US. The company also shared progress on its Horizon yield initiatives and started a Phase III trial for RiaSTAP® AFD.
CSL Seqirus expects stronger H5 avian influenza revenue in the 2nd half and is preparing for the FLUAD® launch in Germany. The Tullamarine facility is advancing through validation. In the CSL Vifor division, demand in the iron therapy market remains high and the nephrology portfolio continues to gain traction. Expansion into new geographies supports additional growth. The company is monitoring recent U.S. tariff developments, noticing that pharmaceutical products remain unaffected for now.
Macquarie Group Ltd (ASX: MQG)
Macquarie Group Limited (ASX: MQG), on 9 May 2025 released its results for the FY5 full year ended 31 March 2025. MQG achieved a full year net profit of $A3,715 million for the year ended 31 March 2025 reflecting a 5% increase over the previous year. The 2nd half of FY25 showed a stronger performance with profit rising 30 percent compared to the first half. Return on equity improved to 11.2%, up from 10.8% the previous year while the annualised return for the second half reached 12.5%. The final ordinary dividend stands at $A3.90 per share, contributing to a total of $A6.50 for FY25 with a payout ratio of 67%. The group, one of the high growth stocks has its financial position remaining strong supported by a capital surplus of $A9.5B and a CET1 ratio of 12.8% well above regulatory requirements.
MAQ Asset Management delivered a profit contribution of $A1,610 million, up 33% YoY. Banking and Financial Services also saw growth, an increase of 11%. Macquarie Capital’s contribution held at $A1,043 million. Of the total net operating income, 54% came from annuity style sources, 17% from market sensitive activities and 29% from areas containing a mix of both.
Assets under management slightly above the prior period touched $A941.0 billion. The group maintains a careful viewpoint given global economic uncertainty, inflation trends and geopolitical risks. A $A2.0 billion share buyback remains active to manage surplus capital. The group is focused on disciplined capital deployment and long-term growth supported by a conservative balance sheet and a risk aware operating model.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
